IIIBIV期经治非小细胞肺癌患者中进
2018-1-31 来源:本站原创 浏览次数:次点击下方,收听SCI天天读57Arandomized,double-blind,placebo-controlled,phaseIIItrialoferlotinibwithorwithoutac-Metinhibitortivantinib(ARQ)inAsianpatientswithpreviouslytreatedstageIIIB/IVnonsquamousnonsmall-celllungcancerharboringwild-typeepidermalgrowthfactorreceptor(ATTENTIONstudy).BACKGROUNDApreviousrandomizedphaseIIstudydemonstratedthattheadditionofac-Metinhibitortivantinibtoanepidermalgrowthfactorreceptor(EGFR)tyrosinekinaseinhibitorerlotinibmightprolongprogression-freesurvival(PFS)inpatientswithpreviouslytreated,nonsquamousnonsmall-celllungcancer(NSCLC).Onasubsetanalysis,thesurvivalbenefitwasgreaterinpatientswithwild-typeEGFR(WT-EGFR)thaninthosewithactivatingEGFRmutations.Herein,thisphaseIIIstudy北京哪有治疗白癜风医院的地址儿童白癜风病的症状